Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Diffuse mesothelioma is an aggressive cancer with limited treatment options and high resistance.
• Anti-apoptotic proteins MCL-1 and BCL-xL contribute to therapeutic resistance by inhibiting apoptosis.
• Understanding resistance mechanisms is crucial for developing effective mesothelioma treatments.

Purpose of the Study:

• To investigate the consistency of B-cell homology domain3 profiles across different mesothelioma models.
• To evaluate the efficacy of co-targeting MCL-1 and BCL-xL in diffuse mesothelioma.
• To identify safe and effective therapeutic strategies for diffuse mesothelioma.

Main Methods:

• B-cell homology domain3 profiling was used to compare tumor samples, patient-derived cells, and xenografts.
• In vitro studies assessed the effects of co-targeting BCL-xL and MCL-1 on cell viability and apoptosis.
• In vivo studies in patient-derived xenografts (PDX) evaluated the therapeutic potential of targeting these proteins.

Main Results:

• B-cell homology domain3 profiles were consistent across intra-patient models, enabling cross-model comparisons.
• Co-targeting BCL-xL and MCL-1 showed synergistic effects on reducing cell viability and increasing apoptosis in vitro.
• In vivo co-targeting led to synthetic lethality in PDX models, indicating a lack of safety for clinical development.
• Targeting MCL-1 alone decreased the apoptosis threshold, enhanced chemosensitivity, and showed no toxicity in PDX models.

Conclusions:

• Targeting MCL-1 alone is a potentially safe strategy to enhance chemotherapy efficacy in diffuse mesothelioma.
• Co-targeting BCL-xL and MCL-1 is not a safe clinical approach due to synthetic lethality.
• Future clinical strategies should focus on MCL-1 inhibition to overcome therapeutic resistance in mesothelioma.